Core Viewpoint - COSCIENS Biopharma Inc. has initiated its Phase 2a clinical efficacy study for its avenanthramides product, aimed at managing inflammation-related conditions, following a successful Phase 1 trial that demonstrated a favorable safety profile [1][4][5]. Group 1: Clinical Study Details - The Phase 1-2a clinical trial, named the AvenActive study, began in November 2023 and involved 72 healthy subjects, with no significant adverse events reported [3][8]. - The Phase 2a study will enroll 20 patients with mild to moderate inflammation, testing doses of 480 mg and 960 mg per day [4][5]. - Initial dosing for the Phase 2a study is expected to occur on March 14, 2025, at the Montreal Heart Institute [4][8]. Group 2: Product Information - Avenanthramides are di-phenolic compounds found in oats, known for their antioxidant and anti-inflammatory properties [2]. - The study will assess inflammatory biomarkers in blood, focusing on cytokines, chemokines, and high-sensitivity C-reactive protein [5]. Group 3: Company Strategy and Market Potential - The successful completion of the Phase 1 study is viewed as a critical milestone, positioning the company for potential out-licensing and commercialization opportunities [6]. - The company aims to become a global leader in natural-based health and wellness products, with avenanthramides seen as a transformative product [6][10].

Core Company Information - COSCIENS Biopharma Inc. is a specialty biopharmaceutical company focused on developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products [3] - The company utilizes proprietary extraction technology to produce active ingredients from renewable plant resources, which are currently used in leading skincare brands [3] - COSCIENS is listed on the NASDAQ Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [4] Recent Developments - A new corporate presentation outlining key development areas and upcoming milestones is scheduled for release in January 2025 [2][10] - The company has streamlined operations and implemented cost-cutting measures to refine its development pathway [10] - Following a merger, the company has prioritized its product pipeline, focusing on high-value opportunities in natural-based products [11] Product Pipeline Updates Pharmaceuticals - The Phase 1 part of the clinical trial for Avenanthramides Tablets has been completed with 72 subjects tested, showing no significant side effects [11] - The Phase 2a efficacy study for Avenanthramides is expected to begin in Q1 2025 and complete by Q3 2025 [11] Cosmeceuticals - Small batches of Enriched Oat Flour with high concentrations of Avenanthramides have been produced and sold for cream formulations [12] - A new website for the JuventeDC product line was launched on December 19, 2024 [12] Nutraceuticals - Yeast Beta Glucan Powder is being finalized in capsule form for commercialization as an immune booster in Q2 2025 [13] - A unique formulation for an Oat Beta Glucan Chewable Bar has been developed, with a commercial launch anticipated in Q1 2025 [13] Macimorelin Update - The DETECT-trial for macimorelin in diagnosing Childhood Onset Growth Hormone Deficiency failed to meet its primary endpoints, leading to a strategic shift in the company's focus [15] - The company will not invest further in macimorelin for Childhood Onset Growth Hormone Deficiency but will maintain its current indication for Adult Growth Hormone Deficiency [15] - Management roles, including that of the Chief Medical Officer, are being reduced to streamline operations and reduce costs [15][16]